+357 96 030922
info@marketpublishers.com

Cell And Gene Therapy CDMO Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

https://marketpublishers.com/r/C4F3275B4728EN.html
Date: September 2025
Pages: 90
Price: US$ 3,200.00 (Single User License)
ID: C4F3275B4728EN

Abstracts

Cell And Gene Therapy CDMO Market Summary

The Cell And Gene Therapy CDMO market provides specialized contract manufacturing and development services for advanced therapeutics, delivering customized solutions for CAR-T, AAV vectors, and stem cell therapies with 95% GMP compliance. This sector is characterized by its high-tech bioreactors, scalable viral vector production, and adherence to FDA and EMA guidelines. Key features include end-to-end services from plasmid design to fill-finish, reducing development timelines by 30%, and cryopreservation for global distribution. The market supports oncology and rare disease therapies, with over 1,200 clinical trials globally. Innovations like single-use bioreactors and AI-optimized yields enhance scalability, while regulatory expertise accelerates approvals. The global Cell And Gene Therapy CDMO market is estimated to reach a valuation of approximately USD 3.0–5.0 billion in 2025, with compound annual growth rates projected in the range of 15%–20% through 2030. Growth is driven by surging demand for personalized medicine, increasing clinical pipelines, and outsourcing trends, positioning CDMOs as critical enablers of next-generation therapies.

Application Analysis and Market Segmentation

OncologyOncology dominates, with CAR-T therapies like Kymriah, growing at 16%–21%. Trends include automated cell processing, cutting costs by 25%, and allogeneic platforms for scalability.

+357 96 030922
info@marketpublishers.com

Infectious DiseasesInfectious disease therapies, like AAV-based vaccines, grow at 15%–20%, with rapid scale-up for pandemics.

Neurological DisordersNeurological therapies, targeting ALS, grow at 14%–19%, with gene editing improving outcomes by 30%.

Rare DiseasesRare disease therapies, like Zolgensma, grow at 15.5%–20.5%, with orphan drug incentives.

OthersOther indications, like cardiovascular, grow at 14%–18%, with niche gene therapies emerging.

By Type

Gene TherapyGene therapies, using AAV vectors, grow at 16%–21%, with high-titer production boosting yields by 20%.

Gene-Modified Cell TherapyCAR-T and TCR therapies grow at 15.5%–20.5%, with automation reducing timelines by 25%.

Cell TherapyStem cell therapies grow at 14.5%–19.5%, with 3D bioprinting gaining traction.

Regional Market Distribution and Geographic Trends

Asia-Pacific: 16%–21% growth, with China’s CGT hubs and Japan’s regulatory incentives.

North America: 15%–20% growth, with U.S. leading in trials and Canada’s gene therapy investments.

Europe: 14.5%–19.5% growth, with Germany’s biotech clusters and UK’s MHRA support.

Latin America: 15%–20% growth, with Brazil’s research hubs and Mexico’s manufacturing.

Middle East & Africa: 14%–19% growth, with UAE’s biotech investments and South Africa’s trial expansions.

+357 96 030922
info@marketpublishers.com

Key Market Players and Competitive Landscape

Lonza: $6B revenue, leads with viral vector platforms, 20% market share.
Catalent: $5B, cell therapy scale-up.
Thermo Fisher Scientific: $40B, end-to-end CDMO services.
FUJIFILM Diosynth: AAV production, $2B revenue.
AGC Biologics: Global manufacturing, 15% YoY growth.
OmniaBio: Canadian cell therapy specialist.
Rentschler Biopharma: EU-focused CDMO.
Charles River Laboratories: Preclinical support.
Novartis: In-house CDMO capabilities.
Boehringer Ingelheim: $25B, gene therapy leader.
WuXi AppTec: APAC scale-up, $5B revenue.
Samsung Biologics: $2B, viral vector specialist.

Industry Value Chain AnalysisThe value chain spans bioprocessing, manufacturing, logistics, and clinical integration.

Raw Materials and Upstream SupplyPlasmids and cell lines sourced from GMP suppliers, with Lonza securing 10,000 liters annually.

Production and ProcessingSingle-use bioreactors produce 1B cells daily, with Catalent scaling 100 batches yearly.

Distribution and LogisticsCryogenic shipping ensures 98% viability.

Downstream Processing and Application Integration

Oncology: CAR-T manufacturing.

Rare Diseases: AAV fill-finish.Downstream yields 30% margins via scalability.

End-User IndustriesBiotech firms capture value through 80% trial success rates.

Market Opportunities and Challenges

OpportunitiesAsia-Pacific’s biotech boom drives outsourcing. Europe’s regulatory support boosts adoption, while Latin America’s research grows. Automation and AI

+357 96 030922
info@marketpublishers.com

enhance yields, and rare disease niches expand.

ChallengesHigh costs—$1M per batch—limit scalability. Regulatory complexity delays approvals by 18 months. Talent shortages impact 10% of projects, while supply chain fragility risks 5% disruptions.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

Please ask for sample pages for full companies list

+357 96 030922
info@marketpublishers.com

Tables & Figures

TABLES AND FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Cell And Gene Therapy CDMO Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Product link: https://marketpublishers.com/r/C4F3275B4728EN.html

Price: US$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C4F3275B4728EN.html